These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 22111941)

  • 1. Specific delivery of kinase inhibitors in nonmalignant and malignant diseases.
    van Beuge MM; Poelstra K; Prakash J
    Expert Opin Drug Deliv; 2012 Jan; 9(1):59-70. PubMed ID: 22111941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protein kinases as targets for cancer treatment.
    Giamas G; Stebbing J; Vorgias CE; Knippschild U
    Pharmacogenomics; 2007 Aug; 8(8):1005-16. PubMed ID: 17716234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal targeting of kinase inhibitors.
    Dolman ME; Fretz MM; Segers GJ; Lacombe M; Prakash J; Storm G; Hennink WE; Kok RJ
    Int J Pharm; 2008 Dec; 364(2):249-57. PubMed ID: 18550305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitors of the anaplastic lymphoma kinase.
    Mologni L
    Expert Opin Investig Drugs; 2012 Jul; 21(7):985-94. PubMed ID: 22612599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic applications of PI3K inhibitors in cardiovascular diseases.
    Ghigo A; Morello F; Perino A; Hirsch E
    Future Med Chem; 2013 Mar; 5(4):479-92. PubMed ID: 23495693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature.
    Dai Y
    Expert Opin Ther Pat; 2010 Jul; 20(7):885-97. PubMed ID: 20509775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular toxicity associated with small molecule tyrosine kinase inhibitors currently in clinical use.
    Dasanu CA; Padmanabhan P; Clark BA; Do C
    Expert Opin Drug Saf; 2012 May; 11(3):445-57. PubMed ID: 22469002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
    Faivre S; Djelloul S; Raymond E
    Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strategies to overcome resistance to targeted protein kinase inhibitors.
    Daub H; Specht K; Ullrich A
    Nat Rev Drug Discov; 2004 Dec; 3(12):1001-10. PubMed ID: 15573099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protein kinase inhibitors: breakthrough medicines and the next generation.
    Sawyer TK; Wu JC; Sawyer JR; English JM
    Expert Opin Investig Drugs; 2013 Jun; 22(6):675-8. PubMed ID: 23705633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PIM1 kinase as a target for cancer therapy.
    Merkel AL; Meggers E; Ocker M
    Expert Opin Investig Drugs; 2012 Apr; 21(4):425-36. PubMed ID: 22385334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potent, selective and orally bioavailable dihydropyrimidine inhibitors of Rho kinase (ROCK1) as potential therapeutic agents for cardiovascular diseases.
    Sehon CA; Wang GZ; Viet AQ; Goodman KB; Dowdell SE; Elkins PA; Semus SF; Evans C; Jolivette LJ; Kirkpatrick RB; Dul E; Khandekar SS; Yi T; Wright LL; Smith GK; Behm DJ; Bentley R; Doe CP; Hu E; Lee D
    J Med Chem; 2008 Nov; 51(21):6631-4. PubMed ID: 18842034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is there a future for Aurora kinase inhibitors for anticancer therapy?
    Carpinelli P; Moll J
    Curr Opin Drug Discov Devel; 2009 Jul; 12(4):533-42. PubMed ID: 19562649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of intrinsic and acquired resistance to kinase-targeted therapies.
    Bagrodia S; Smeal T; Abraham RT
    Pigment Cell Melanoma Res; 2012 Nov; 25(6):819-31. PubMed ID: 22883054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer.
    Roberts PJ; Der CJ
    Oncogene; 2007 May; 26(22):3291-310. PubMed ID: 17496923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting Polo-like kinase in cancer therapy.
    Degenhardt Y; Lampkin T
    Clin Cancer Res; 2010 Jan; 16(2):384-9. PubMed ID: 20068088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Danusertib, an aurora kinase inhibitor.
    Meulenbeld HJ; Mathijssen RH; Verweij J; de Wit R; de Jonge MJ
    Expert Opin Investig Drugs; 2012 Mar; 21(3):383-93. PubMed ID: 22242557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting protein kinases.
    Melnikova I; Golden J
    Nat Rev Drug Discov; 2004 Dec; 3(12):993-4. PubMed ID: 15645605
    [No Abstract]   [Full Text] [Related]  

  • 19. Strategies for the selective regulation of kinases with allosteric modulators: exploiting exclusive structural features.
    Fang Z; Grütter C; Rauh D
    ACS Chem Biol; 2013 Jan; 8(1):58-70. PubMed ID: 23249378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Losmapimod: a novel drug against cardiovascular diseases?].
    Dewenter M; Vettel C; El-Armouche A
    Dtsch Med Wochenschr; 2013 Jan; 138(1-2):39-42. PubMed ID: 23250695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.